SEC Form 4 · accession 0000899243-18-018155
Aptinyx Inc. · APTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Koppel
Director
Period of report
Jun 25, 2018
Accepted (ET)
Jun 26, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674365
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1,F2 | Jun 25, 2018 | C | 1,825,092 | — | A | 1,825,092 | I | See Footnotes |
| Common StockF4,F1,F2 | Jun 25, 2018 | P | 400,000 | $16.00 | A | 2,225,092 | I | See Footnotes |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred StockF3,F1,F2 | — | Jun 25, 2018 | C | 50,347,397 | D | — | — | Common Stock | 1,825,092 | 0 | I |
Explanation of responses
- F1Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities").
- F2The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- F3Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date.
- F4On June 25, 2018, the Bain Life Sciences Entities purchased, in aggregate, 400,000 shares of Common Stock of the Issuer at a price of $16.00 per share, pursuant to an underwritten public offering.